학술논문
Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
Document Type
article
Author
Source
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-5 (2021)
Subject
Language
English
ISSN
1742-6405
Abstract
Abstract Objective The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically suppressed people living with HIV (PLWH). We analyzed virologic outcomes with respect to treatment history and HIV drug resistance. Design Post hoc analysis of a randomized trial. Methods Main inclusion criteria were an HIV RNA level